OR WAIT 15 SECS
PHARMASEAL, a provider of clinical trial management and governance solutions, announces a second major release of its Engility CTMS platform. New features include site monitoring, issue management, and global access management.
With a focus on configurability and collaboration, the Engility CTMS monitoring module provides a workspace to manage all monitoring visits (onsite/remote/telephone) via an intuitive interface to support working in the system.
Commenting on the enhanced platform, Daljit Cheema, CEO and Founder of PHARMASEAL said: “Engility CTMS is a SaaS cloud platform built with agility at its core and engineered to evolve. PHARMASEALS’ collective passion for continuous innovation leads to capabilities, such as the monitoring module, so that biopharmaceutical sponsors and medical device companies of all sizes can proactively and collaboratively adopt an innovative approach.”
Flexible and scalable in order to meet the needs of all organisations, Engility CTMS enables data driven decision-making.
Further information can be found at www.pharmaseal.co